A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study

被引：9

作者：

Molina, J. R.

Dy, G. K.

Foster, N. R.

Ziegler, K. L. Allen

Adjei, A.

Rowland, K. M.

Aubry, M.

Flynn, P. J.

Mandrekar, S. J.

Schild, S. E.

Adjei, A. A.

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[3] North Cent Canc Treatment Grp, Rochester, MN USA

[4] Carle Clin Associates, Urbana, IL USA

[5] Metro Minnesota Community Clin Oncol Project, St Louis Pk, MN USA

[6] NCCTG, Rochester, MN USA

[7] Mayo Clin, Scottsdale, AZ USA

来源：

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.7513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7513

引用

页数：1